Mixing Business And Philanthropy Yields Returns For Glaxo In Africa
This article was originally published in PharmAsia News
GlaxoSmithKline is having success with its "hybrid" approach in Africa, combining no-nonsense business with the aim of improving access to medicines there – in part through deeply discounted prices, measuring managers’ sales performances by the amount of drugs sold, rather than profits, and reinvesting in health infrastructure.
You may also be interested in...
In another effort to boost development of malaria medicines GlaxoSmithKline is providing free public access to its library of 13,500 compounds that have shown some activity against the disease
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.
Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.